Ceramedix Holding, Llc
CAGE Code: 7SUF5
NCAGE Code: 7SUF5
Status: Active
Type: Commercial Supplier
Summary
Ceramedix Holding, Llc is an Active Commercial Supplier with the Cage Code 7SUF5.
Address
555 Madison Ave Ste 1201
New York NY 10022-3328
United States
Points of Contact
No Points of Contact...
Related Information
No Related Information...
People who viewed this 'CAGE Code' also viewed...
Tempo Sense Inc Trumeter Co Inc Doctors Without Borders Lorrillard Tobacco Co Industrial Scientific Co Amerotron Corp Fuller George A Co Div Of Northrop Standard Industries Inc M Rosenblatt & Son Inc American Business Machines Inc Associated American Trading Div Of Syrkus And Guttman Inc Rhi Entertainment Inc A B C Inc Play Co Toys Inc Buttling Padgett Co Inc Mutual Electric And Machine Corp Vulcan Machine And Mfg Inc Anchor Steel Co National Ignition Mfg Co Inc
Frequently Asked Questions (FAQ) for CAGE 7SUF5
- What is CAGE Code 7SUF5?
- 7SUF5 is the unique identifier used by NATO Organizations to reference the physical entity known as Ceramedix Holding, Llc located at 555 Madison Ave Ste 1201, New York NY 10022-3328, United States.
- Who is CAGE Code 7SUF5?
- 7SUF5 refers to Ceramedix Holding, Llc located at 555 Madison Ave Ste 1201, New York NY 10022-3328, United States.
- Where is CAGE Code 7SUF5 Located?
- CAGE Code 7SUF5 is located in New York, NY, USA.
Contracting History for CAGE 7SUF5 Most Recent 25 Records
- 75N93023C00015
- Development Of Anticeramide Treatment As A Novel Medical Countermeasure For Acute Effects Of Radiation Exposure
- 14 Aug 2023
- Development Of Anticeramide Treatment As A Novel Medical Countermeasure For Acute Effects Of Radiation Exposure
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $1,429,485.00
- Department Of Health And Human Services (Hhs)
- 75N93023C00015
- Development Of Anticeramide Treatment As A Novel Medical Countermeasure For Acute Effects Of Radiation Exposure
- 22 Aug 2023
- Development Of Anticeramide Treatment As A Novel Medical Countermeasure For Acute Effects Of Radiation Exposure
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $1,529,485.00
- Department Of Health And Human Services (Hhs)
- 75N93023C00015
- Development Of Anticeramide Treatment As A Novel Medical Countermeasure For Acute Effects Of Radiation Exposure
- 29 Jun 2023
- Development Of Anticeramide Treatment As A Novel Medical Countermeasure For Acute Effects Of Radiation Exposure
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $1,429,485.00
- Department Of Health And Human Services (Hhs)
- W81XWH20C0042
- Jw190496 Fy19 New Start
- 26 Jan 2023
- Jw190496 Fy19 New Start
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $4,496,897.16
- Department Of Defense (Dod)
- W81XWH20C0042
- Jw190496 Fy19 New Start Research And Development Contract Project Title: Anticeramide Scfv As Prophylaxis Of The Radiation Gi Syndrome
- 10 Jul 2023
- Jw190496 Fy19 New Start Research And Development Contract Project Title: Anticeramide Scfv As Prophylaxis Of The Radiation Gi Syndrome
- Army Med Res Acq Activity
- Department Of Defense (Dod)
- $4,496,897.16
- Department Of Defense (Dod)
- W81XWH20C0042
- Jw190496 Fy19 New Start
- 5 Oct 2021
- Jw190496 Fy19 New Start
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $4,496,897.16
- Department Of Defense (Dod)
- W81XWH20C0042
- Jw190496 Fy19 New Start
- 12 Oct 2021
- Jw190496 Fy19 New Start
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $4,496,897.16
- Department Of Defense (Dod)
- W81XWH20C0042
- Anticeramide Scfv As Prophylaxis Of The Radiation Gi Syndrom For The Joint Warfighter Medical Research Program
- 20 May 2022
- Anticeramide Scfv As Prophylaxis Of The Radiation Gi Syndrom For The Joint Warfighter Medical Research Program
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $4,496,897.16
- Department Of Defense (Dod)